Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)

Схожі ресурси

• Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
  за авторством: Kalra, Philip A.
  Опубліковано: (2011)
• A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
  за авторством: Bhandari, Sunil, та інші
  Опубліковано: (2015)
• Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
  за авторством: Kalra, Philip A, та інші
  Опубліковано: (2016)
• A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
  за авторством: Reinisch, Walter, та інші
  Опубліковано: (2013)
• The effect of perioperative intravenously administered iron isomaltoside 1000 (Monofer®) on transfusion requirements for patients undergoing complex valvular heart surgery: study protocol for a randomized controlled trial
  за авторством: Lee, Seung Hyun, та інші
  Опубліковано: (2018)